31st Aug 2020 07:38
(Alliance News) - A study has found the drug Farxiga can significantly prolong life in patients with chronic kidney disease, maker AstraZeneca PLC said Sunday.
Farxiga, whose generic name is dapagliflozin, on top of standard of care reduced the worsening of renal function or risk of cardiovascular or renal death by 39% compared to placebo in patients with chronic kidney disease, in a Phase III test, Astra said.
The results of the Phase III DAPA-CKD trial were presented by the Cambridge, England-based pharmaceutical firm on Sunday at the ESC Congress 2020, organised by the European Society of Cardiology.
Chronic kidney disease is a serious, progressive condition defined by decreased kidney function and affecting nearly 700 million people worldwide, Astra said.
"With today's results, Farxiga becomes the first SGLT2 inhibitor proven to significantly prolong the survival of patients with chronic kidney disease with and without type-2 diabetes," said Mene Pangalos, executive vice president for BioPharmaceuticals R&D at Astra.
"Farxiga is also the first medicine in its class to demonstrate benefit in treating both heart failure and chronic kidney disease in patients with and without type-2 diabetes, and reduce the risk of hospitalisation for heart failure and nephropathy in type-2 diabetes."
Back in May, Farxiga was approved in the US to reduce the risk of cardiovascular death and hospitalisation for heart failure in adults with heart failure with reduced ejection fraction.
By Tom Waite; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Astrazeneca